Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival

Apoptosis

Volumn 13, Issue 6, 2008, Pages 790-802

  Johnson, Geoffrey E ^a,b   Ivanov, Vladimir N ^a   Hei, Tom K ^a,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Columbia University ^*  (United States)

^c NONE   (United States)

Author keywords

AKT; COX 2; Melanoma; Radioresistance; TRAIL

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ACTIVATING TRANSCRIPTION FACTOR 2; ATM PROTEIN; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOHEXIMIDE; CYCLOOXYGENASE 2; DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 1; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P53; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; REGULATOR PROTEIN; RESVERATROL; SMALL INTERFERING RNA; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FKHRL1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL SURFACE; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; GAMMA IRRADIATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; RADIOSENSITIZATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CHROMONES; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2 INHIBITORS; GAMMA RAYS; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MORPHOLINES; NITROBENZENES; RADIATION-SENSITIZING AGENTS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STILBENES; SULFONAMIDES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 44149095198     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-008-0212-y     Document Type: Article

References (40)

1. Debatin KM, Krammer PH (2004) Death receptors in chemotherapy and cancer. Oncogene 23:2950-2966
2. Okada H, Mak TW (2004) Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 4:592-603
3. Cory S, Adams JM (2005) Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 8:5-6
4. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431-436
5. Krammer PH, Kaminski M, Kiessling M, Gulow K (2007) No life without death. Adv Cancer Res 97C:111-138
6. Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, Compaan D, Lowman H, Hymowitz S, Ashkenazi A (2008) Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 15:751-761
7. Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2:420-430
8. Schaefer U, Voloshanenko O, Willen D, Walczak H (2007) TRAIL: a multifunctional cytokine. Front Biosci 12:3813-3824
9. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A (2000) Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 97:1754-1759
10. Ivanov VN, Zhou H, Hei TK (2007) Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells. Cancer Res 67:5397-5407
11. Subbaramaiah K, Dannenberg AJ (2003) Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24:96-102
12. Luo J, Manning BD, Cantley LC (2003) Targeting the PI3K-AKT pathway in human cancer: rationale and promise. Cancer Cell 4:257-262
13. Satyamoorthy K, Chehab NH, Waterman MJ, Lien MC, El-Deiry WS, Herlyn M, Halazonetis TD (2000) Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ 11:467-474
14. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8:275-283
15. Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, Zhang W, Plunkett W, Huang P (2006) Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol 175:913-923
16. Gogvadze V, Orrenius S, Zhivotovsky B (2008) Mitochondria in cancer cells: what is so special about them? Trends Cell Biol 18:165-173
17. Ivanov VN, Partridge MA, Johnson GE, Huang SX, Zhou H, Hei TK (2008) Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp Cell Res 314:1163-1176
18. Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, Rendle S, Elder DE, Herlyn M (1997) Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res 7(Suppl 2):S35-S42
19. van Dam H, Huguier S, Kooistra K, Baguet J, Vial E, van der Eb AJ, Herrlich P, Angel P, Castellazzi M (1998) Autocrine growth and anchorage independence: two complementing Jun-controlled genetic programs of cellular transformation. Genes Dev 12:1227-1239
20. Baetu TM, Kwon H, Sharma S, Grandvaux N, Hiscott J (2001) Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. J Immunol 167:3164-3173
21. Bartke T, Siegmund D, Peters N, Reichwein M, Henkler F, Scheurich P, Wajant H (2001) p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 20:571-580
22. Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, El-Deiry WS (2004) Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 24:8541-8555
23. Resnick-Silverman L, St Clair S, Maurer M, Zhao K, Manfredi JJ (1998) Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev 12:2102-2107
24. Bakhtiarova A, Taslimi P, Elliman SJ, Kosinski PA, Hubbard B, Kavana M, Kemp DM (2006) Resveratrol inhibits firefly luciferase. Biochem Biophys Res Commun 351:481-484
25. Ivanov VN, Hei TK (2004) Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway. J Biol Chem 279:22747-22758
26. Shiloh Y (2006) The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci 31:402-410
27. Nagata S (1999) Fas ligand-induced apoptosis. Annu Rev Genet 33:29-55
28. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218-220
29. Ivanov VN, Partridge MA, Johnson GE, Huang SXL, Zhou H, Hei TK (2008) Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp Cell Res 314:1163-1176
30. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y (2004) Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24:2783-2840
31. Kotha A, Sekharam M, Cilenti L, Siddiquee K, Khaled A, Zervos AS, Carter B, Turkson J, Jove R (2006) Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 5:621-629
32. Rigel DS, Friedman RJ, Kopf AW (1996) The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Derm 34:839-847
33. Rigel DS (2002) The effect of sunscreen on melanoma risk. Derm Clin 20:601-606
34. Perlis C, Herlyn M (2004) Recent advances in melanoma biology. Oncologist 9:182-187
35. Atkins MB (2006) Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 12:2353s-2358s
36. Oehler C, Dickinson DJ, Broggini-Tenzer A, Hofstetter B, Hollenstein A, Riesterer O, Vuong V, Pruschy M (2007) Current concepts for the combined treatment modality of ionizing radiation with anticancer agents. Curr Pharm Des 13:519-535
37. Gwosdz C, Scheckenbach K, Lieven O, Reifenberger J, Knopf A, Bier H, Balz V (2006) Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas. Int J Cancer 118:577-582
38. Hersey P, Zhang XD (2001) How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 1:142-150
39. Fulda S, Debatin KM (2004) Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 64:337-346
40. Shankar S, Singh G, Srivastava RK (2007) Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci 12:4839-4854